Kim M. Keeling, Ph.D. - Publications

2000 University of Alabama, Birmingham, Birmingham, AL, United States 
Genetics, Molecular Biology

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Leier A, Bedwell DM, Chen AT, Dickson G, Keeling KM, Kesterson RA, Korf BR, Marquez Lago TT, Müller UF, Popplewell L, Zhou J, Wallis D. Mutation-Directed Therapeutics for Neurofibromatosis Type I. Molecular Therapy. Nucleic Acids. 20: 739-753. PMID 32408052 DOI: 10.1016/j.omtn.2020.04.012  0.96
2020 Keeling KM, Bedwell DM. Finding sense in the context. Elife. 9. PMID 32202493 DOI: 10.7554/eLife.55960  0.96
2017 Xue X, Mutyam V, Thakerar A, Mobley J, Bridges RJ, Rowe SM, Keeling KM, Bedwell DM. Identification of the Amino Acids Inserted During Suppression of CFTR Nonsense Mutations and Determination of Their Functional Consequences. Human Molecular Genetics. PMID 28575328 DOI: 10.1093/hmg/ddx196  0.96
2016 Roy B, Friesen WJ, Tomizawa Y, Leszyk JD, Zhuo J, Johnson B, Dakka J, Trotta CR, Xue X, Mutyam V, Keeling KM, Mobley JA, Rowe SM, Bedwell DM, Welch EM, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proceedings of the National Academy of Sciences of the United States of America. PMID 27702906 DOI: 10.1073/pnas.1605336113  0.96
2016 Mutyam V, Du M, Xue X, Keeling KM, White EL, Bostwick JR, Rasmussen L, Liu B, Mazur M, Hong JS, Falk Libby E, Liang F, Shang H, Mense M, Suto MJ, et al. Discovery of Clinically Approved Agents That Promote Suppression of CFTR Nonsense Mutations. American Journal of Respiratory and Critical Care Medicine. PMID 27104944 DOI: 10.1164/rccm.201601-0154OC  0.96
2014 Keeling KM, Xue X, Gunn G, Bedwell DM. Therapeutics based on stop codon readthrough. Annual Review of Genomics and Human Genetics. 15: 371-94. PMID 24773318 DOI: 10.1146/annurev-genom-091212-153527  0.96
2014 Gunn G, Dai Y, Du M, Belakhov V, Kandasamy J, Schoeb TR, Baasov T, Bedwell DM, Keeling KM. Long-term nonsense suppression therapy moderates MPS I-H disease progression. Molecular Genetics and Metabolism. 111: 374-81. PMID 24411223 DOI: 10.1016/j.ymgme.2013.12.007  0.96
2013 Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, Belakhov V, Kandasamy J, Velu SE, Baasov T, Bedwell DM. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. Plos One. 8: e60478. PMID 23593225 DOI: 10.1371/journal.pone.0060478  0.96
2012 Keeling KM, Wang D, Conard SE, Bedwell DM. Suppression of premature termination codons as a therapeutic approach. Critical Reviews in Biochemistry and Molecular Biology. 47: 444-63. PMID 22672057 DOI: 10.3109/10409238.2012.694846  0.96
2012 Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, Li YT, Bedwell DM, Keeling KM. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Molecular Genetics and Metabolism. 105: 116-25. PMID 22056610 DOI: 10.1016/j.ymgme.2011.10.005  0.96
2011 Keeling KM, Bedwell DM. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdisciplinary Reviews. Rna. 2: 837-52. PMID 21976286 DOI: 10.1002/wrna.95  0.96
2011 Lazrak A, Jurkuvenaite A, Chen L, Keeling KM, Collawn JF, Bedwell DM, Matalon S. Enhancement of alveolar epithelial sodium channel activity with decreased cystic fibrosis transmembrane conductance regulator expression in mouse lung. American Journal of Physiology. Lung Cellular and Molecular Physiology. 301: L557-67. PMID 21743028 DOI: 10.1152/ajplung.00094.2011  0.96
2010 Wang D, Shukla C, Liu X, Schoeb TR, Clarke LA, Bedwell DM, Keeling KM. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Molecular Genetics and Metabolism. 99: 62-71. PMID 19751987 DOI: 10.1016/j.ymgme.2009.08.002  0.96
2010 Wang D, Shukla C, Liu X, Schoeb TR, Clarke LA, Bedwell DM, Keeling KM. Corrigendum to "Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation" [Mol. Genet. Metab. 99 (2010) 62-71] (DOI:10.1016/j.ymgme.2009.08.002) Molecular Genetics and Metabolism. 99: 439. DOI: 10.1016/j.ymgme.2009.12.013  0.96
2009 Du M, Keeling KM, Fan L, Liu X, Bedwell DM. Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. The Journal of Biological Chemistry. 284: 6885-92. PMID 19136563 DOI: 10.1074/jbc.M806728200  0.96
2008 Fan-Minogue H, Du M, Pisarev AV, Kallmeyer AK, Salas-Marco J, Keeling KM, Thompson SR, Pestova TV, Bedwell DM. Distinct eRF3 requirements suggest alternate eRF1 conformations mediate peptide release during eukaryotic translation termination. Molecular Cell. 30: 599-609. PMID 18538658 DOI: 10.1016/j.molcel.2008.03.020  0.96
2006 Kallmeyer AK, Keeling KM, Bedwell DM. Eukaryotic release factor 1 phosphorylation by CK2 protein kinase is dynamic but has little effect on the efficiency of translation termination in Saccharomyces cerevisiae. Eukaryotic Cell. 5: 1378-87. PMID 16896221 DOI: 10.1128/EC.00073-06  0.96
2006 Keeling KM, Salas-Marco J, Osherovich LZ, Bedwell DM. Tpa1p is part of an mRNP complex that influences translation termination, mRNA deadenylation, and mRNA turnover in Saccharomyces cerevisiae. Molecular and Cellular Biology. 26: 5237-48. PMID 16809762 DOI: 10.1128/MCB.02448-05  0.96
2006 Du M, Keeling KM, Fan L, Liu X, Kovaçs T, Sorscher E, Bedwell DM. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. Journal of Molecular Medicine (Berlin, Germany). 84: 573-82. PMID 16541275 DOI: 10.1007/s00109-006-0045-5  0.96
2006 Kellermayer R, Szigeti R, Keeling KM, Bedekovics T, Bedwell DM. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. The Journal of Investigative Dermatology. 126: 229-31. PMID 16417242 DOI: 10.1038/sj.jid.5700031  0.96
2005 Keeling KM, Bedwell DM. Pharmacological suppression of premature stop mutations that cause genetic diseases Current Pharmacogenomics. 3: 259-269. DOI: 10.2174/157016005774913149  0.96
2004 Keeling KM, Lanier J, Du M, Salas-Marco J, Gao L, Kaenjak-Angeletti A, Bedwell DM. Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae. Rna (New York, N.Y.). 10: 691-703. PMID 15037778 DOI: 10.1261/rna.5147804  0.96
2002 Du M, Jones JR, Lanier J, Keeling KM, Lindsey JR, Tousson A, Bebök Z, Whitsett JA, Dey CR, Colledge WH, Evans MJ, Sorscher EJ, Bedwell DM. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. Journal of Molecular Medicine (Berlin, Germany). 80: 595-604. PMID 12226741 DOI: 10.1007/s00109-002-0363-1  0.96
2002 Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. Journal of Molecular Medicine (Berlin, Germany). 80: 367-76. PMID 12072912 DOI: 10.1007/s00109-001-0317-z  0.96
2001 Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Human Molecular Genetics. 10: 291-9. PMID 11159948  0.96
Show low-probability matches.